Polyglutamine diseases: emerging concepts in pathogenesis and therapy

被引:210
作者
Shao, Jieya
Diamond, Marc I.
机构
[1] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA
关键词
D O I
10.1093/hmg/ddm213
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Polyglutamine diseases are a family of neurodegenerative conditions that each derive from a CAG triplet repeat expansion in a specific gene. This produces a pathogenic protein that contains a critically expanded tract of glutamines. These prototypical protein misfolding disorders include Huntington disease, spinobulbar muscular atrophy, dentatorubral-pallidoluysian atrophy and several spinocerebellar ataxias. This article reviews the emerging concepts in pathogenesis and therapy. Key ideas include the role of proteolytic cleavage, the importance of conformational change in the pathogenic proteins, the role of protein aggregation and the importance of transcriptional and metabolic disturbances. The relative role of functional perturbation in a target protein induced by a polyglutamine expansion is also discussed. Therapeutic strategies include counteracting cellular perturbations and direct targeting of polyglutamine protein expression, cleavage or conformation.
引用
收藏
页码:R115 / R123
页数:9
相关论文
共 139 条
[1]   PHYSICAL MAP ACROSS CHROMOSOME 11Q22-Q23 CONTAINING THE MAJOR LOCUS FOR ATAXIA-TELANGIECTASIA [J].
AMBROSE, HJ ;
BYRD, PJ ;
MCCONVILLE, CM ;
COOPER, PR ;
STANKOVIC, T ;
RILEY, JH ;
SHILOH, Y ;
MCNAMARA, JO ;
FUKAO, T ;
TAYLOR, AMR .
GENOMICS, 1994, 21 (03) :612-619
[2]   Striatal glucose metabolism and dopamine D-2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease [J].
Antonini, A ;
Leenders, KL ;
Spiegel, R ;
Meier, D ;
Vontobel, P ;
WeigellWeber, M ;
SanchezPernaute, R ;
deYebenez, JG ;
Boesiger, P ;
Weindl, A ;
Maguire, RP .
BRAIN, 1996, 119 :2085-2095
[3]   Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death [J].
Arrasate, M ;
Mitra, S ;
Schweitzer, ES ;
Segal, MR ;
Finkbeiner, S .
NATURE, 2004, 431 (7010) :805-810
[4]   Experimental therapeutics in transgenic mouse models of Huntington's disease [J].
Beal, MF ;
Ferrante, RJ .
NATURE REVIEWS NEUROSCIENCE, 2004, 5 (05) :373-384
[5]   Impairment of the ubiquitin-proteasome system by protein aggregation [J].
Bence, NF ;
Sampat, RM ;
Kopito, RR .
SCIENCE, 2001, 292 (5521) :1552-1555
[6]   Rapamycin alleviates toxicity of different aggregate-prone proteins [J].
Berger, Z ;
Ravikumar, B ;
Menzies, FM ;
Oroz, LG ;
Underwood, BR ;
Pangalos, MN ;
Schmitt, I ;
Wullner, U ;
Evert, BO ;
O'Kane, CJ ;
Rubinsztein, DC .
HUMAN MOLECULAR GENETICS, 2006, 15 (03) :433-442
[7]   Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes [J].
Bowman, Aaron B. ;
Lam, Yung C. ;
Jafar-Nejad, Paymaan ;
Chen, Hung-Kai ;
Richman, Ronald ;
Samaco, Rodney C. ;
Fryer, John D. ;
Kahle, Juliette J. ;
Orr, Harry T. ;
Zoghbi, Huda Y. .
NATURE GENETICS, 2007, 39 (03) :373-379
[8]   The energetics of Huntington's disease [J].
Browne, SE ;
Beal, MF .
NEUROCHEMICAL RESEARCH, 2004, 29 (03) :531-546
[9]   Oxidative damage in Huntington's disease pathogenesis [J].
Browne, Susan E. ;
Beal, M. Flint .
ANTIOXIDANTS & REDOX SIGNALING, 2006, 8 (11-12) :2061-2073
[10]   The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity [J].
Burnett, B ;
Li, FS ;
Pittman, RN .
HUMAN MOLECULAR GENETICS, 2003, 12 (23) :3195-3205